| Literature DB >> 28972968 |
Wan-Hua Hsieh1, I-Feng Lin2, Jung-Chun Ho3,4, Peter Wushou Chang5,6.
Abstract
BACKGROUND: The current study followed-up site-specific cancer risks in an unique cohort with 30 years' follow-up after long-term low-dose-rate radiation exposure in Taiwan.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28972968 PMCID: PMC5729469 DOI: 10.1038/bjc.2017.350
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Characteristics of the cohort population in radio-contaminated buildings (RCB cohort) by solid cancers and leukaemia
| Overall | 6242 (100) | 247 | 236 | 97 106 | 24.3 | 11 | 14 7984 | 0.74 |
| Sex | ||||||||
| Male | 2968 (47.5) | 113 | 106 | 45 890 | 23.1 | 7 | 69 849 | 1.00 |
| Female | 3274 (52.5) | 134 | 130 | 51 216 | 25.38 | 4 | 78 135 | 0.51 |
| Age at initial exposure (years) | ||||||||
| <20 | 3907 (62.6) | 43 | 40 | 58 778 | 6.81 | 3 | 90 191 | 0.33 |
| 20–39 | 1721 (27.6) | 112 | 108 | 29 614 | 36.47 | 4 | 43979 | 0.91 |
| ⩾40 | 614 (9.8) | 92 | 88 | 8714 | 100.99 | 4 | 13814 | 2.90 |
| Mean; median (range) | 16.9; 9.7 (<0–87) | |||||||
| Cumulative exposure (Taiwan Cumulative Dose; mSv) | ||||||||
| <5 | 2932 (47.0) | 79 | 79 | 41 671 | 18.96 | 0 | 65 448 | 0 |
| 5–99 | 2752 (44.1) | 122 | 114 | 46 137 | 24.71 | 8 | 68 620 | 1.17 |
| ⩾100 | 558 (8.9) | 46 | 43 | 9298 | 46.25 | 3 | 13 916 | 2.16 |
| Mean; median (range) | 47.7; 6.3 (<1∼2363) | |||||||
Cancers with assumed minimum latent periods (leukaemia: 2 years; solid cancers: 10 years); Incidence rates are per 10 000 person years accounting for assumed minimum latent periods.
Adjusted hazard ratio associated with a 100-mSv increase in cumulative exposure
| All cancers | 249 | 1.05 | (1.00, 1.08) | 0.04 | 282 | 1.05 | (1.00, 1.08) | 0.03 |
| All cancers excluding leukaemia | 241 | 1.04 | (1.00, 1.08) | 0.08 | 274 | 1.04 | (1.00, 1.08) | 0.05 |
| All solid cancers | 236 | 1.04 | (1.00, 1.08) | 0.07 | 269 | 1.04 | (1.01, 1.08) | 0.04 |
| Female breast | 35 | 1.11 | (1.05, 1.20) | 0.008 | 40 | 1.12 | (1.04, 1.17) | 0.002 |
| Cervix uteri | 24 | 1.10 | (0.96, 1.20) | 0.10 | 28 | 1.09 | (0.97, 1.17) | 0.13 |
| Lung | 24 | 1.10 | (1.00, 1.17) | 0.05 | 27 | 1.12 | (1.04, 1.18) | 0.004 |
| Thyroid gland | 20 | 1.06 | (0.83, 1.17) | 0.52 | 25 | 1.03 | (0.80, 1.15) | 0.75 |
| Liver | 18 | 1.05 | (0.88, 1.15) | 0.52 | 19 | 1.04 | (0.88, 1.14) | 0.57 |
| Stomach | 13 | 1.08 | (0.92, 1.19) | 0.27 | 15 | 1.10 | (0.97, 1.19) | 0.10 |
| Rectum | 16 | 1.03 | (0.73, 1.17) | 0.78 | 17 | 1.02 | (0.71, 1.16) | 0.87 |
| Leukaemia excluding MM&CLL | 8 | 1.18 | (1.04, 1.28) | 0.006 | 8 | 1.18 | (1.04, 1.28) | 0.006 |
| Leukaemia excluding CLL | 11 | 1.15 | (1.03, 0.24) | 0.012 | 11 | 1.15 | (1.03, 1.24) | 0.012 |
Cancers with minimum latent periods (leukaemia:2 years; solid cancers:10 years or 5 years).
HR were adjusted for initial exposure age, 90% CI were partial likelihood-based, and P-values were two-sided.
CLL=chronic lymphocitic leukaemia; MM=multiple myeloma.
Relative hazards (HRs) of breast cancers by the initial age of exposure
| TCD <5 mSv | 10 | 14131 | 7.1 | 1 | ||
| TCD 5–100 mSv | 11 | 19816 | 5.6 | 0.88 | 0.43, 1.82 | 0.76 |
| TCD ⩾100 mSv | 7 | 5123 | 13.7 | 2.07 | 0.89, 4.62 | 0.14 |
| TCD 100 mSv (test for linear trend) | 1.07 | 0.98, 1.14 | 0.14 | |||
| TCD <5 mSv | 1 | 27829 | 0.4 | 1 | ||
| TCD 5–100 mSv | 4 | 26792 | 1.5 | 3.02 | 0.59, 31.82 | 0.33 |
| TCD ⩾100 mSv | 2 | 4321 | 4.6 | 10.91 | 1.55, 125.9 | 0.05 |
| TCD 100 mSv (test for linear trend) | 1.38 | 1.14, 1.60 | 0.0008 | |||
Abbreviations: CI=confidence interval; HR=Hazards ratio; IAE=initial age at exposure; TCD=Taiwan Cumulative Dose; person-years accounted for minimum latent periods as stated in Table 2.
Breast cancers with minimum latent periods 10 years.